DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1956)

Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2018

Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2018

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets under study, and neither agent is approved to treat esophageal cancer. Roche/Genentech/Chugai’s Herceptin is the first-line standard of care for HER2-positive metastatic patients, and Eli Lilly’s Cyramza is approved for patients with advanced disease following fluoropyrimidine- and platinum-based therapy. Additionally, two PD-1 inhibitors—Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (Japan only) and Merck & Co.’s Keytruda (United States only)—are approved to treat third- and later-line gastric and GEJadenocarcinoma. Despite these approvals, the gastroesophageal cancer therapy market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; agents span a range of drug classes and target various gastroesophageal cancer populations associated with significant unmet need. These treatments may soon offer patients a more-optimistic outlook.

Questions Answered

  • How do current treatment practices differ between esophageal, gastric, and GEJcancer, and which populations provide the greatest drug-treatment opportunities by geography?
  • What are interviewed thought leaders’ insights on Herceptin, Cyramza, Keytruda, Opdivo, and chemotherapy? What clinical needs remain unfulfilled, and on which opportunities can developers capitalize?
  • Which other immune checkpoint inhibitors (Bavencio, Yervoy, tislelizumab) are expected to be approved and in which disease setting(s), and how will they compete with currently marketed and established therapies?
  • What agents with novel mechanisms of action are being assessed in Phase III trials, which populations are they targeting, and how will they impact the gastroesophageal cancer therapy market?
  • What are the market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Already a Client? Log in to access this report.

  • Pub Date: December 2018

Purchase Report

Recent reports:
You may also be interested in: